ILD trials resulted in a nominally significant reduction in the risk of death by 59% in patients who received 18mg nerandomilast without background therapy versus placebo.1Both FIBRONEER™ phase III ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback